Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Live webcast presentation on Wednesday, March 20th at 11:50 AM ET

THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced today that Lori Bisson, Chief Executive Officer of Autonomix will present at the Benzinga Virtual Healthcare Summit 2024 on Wednesday, March 20, 2024 at 11:50 AM ET.

Benzinga’s Virtual Healthcare Summit is a virtual event where the brightest minds in healthcare, influential companies, analysts, and thought leaders converge to shape the future of health. Join the event for a dynamic exploration of the healthcare and biotech landscape, covering topics including AI, telemedicine, oncology, medical devices, healthcare M&A activity, and the latest start-ups.

To register for the event and access the Autonomix presentation, please visit the Benzinga Virtual Healthcare Summit 2024 event website.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com

Staff

Recent Posts

TE Connectivity declares quarterly dividend

GALWAY, Ireland, June 11, 2025 /PRNewswire/ -- TE Connectivity plc (NYSE: TEL) announced today that…

9 minutes ago

SRM Equity Partners Acquires RF Technologies, a Leader in Safety and Security Solutions for Healthcare and Senior Living

BROOKFIELD, Wis., June 11, 2025 /PRNewswire/ -- SRM Equity Partners ("SRM"), an operationally focused private…

9 minutes ago

New Findings from NSC Grant Recipients Help Tackle America’s Most Common Workplace Injury

MSD Solutions Lab programs unite academic researchers and industry partners to drive innovation WASHINGTON, June…

9 minutes ago

Version 3.0 AI Automation Platform Launches at VGM’s Heartland Conference

Darby 3.0 automates patient intake workflows from fax to EMR, helping HME providers scale without…

9 minutes ago

AllSci Wins Grant to Expand AI Platform for Pharma and Biotech R&D: Accelerating Hypothesis-Driven Discovery

Empowering researchers at every level to test hypotheses, validate findings, and collaborate to advance science…

9 minutes ago

RIVANNA selected for prestigious MedTech Innovator 2025 Accelerator Cohort

— One of 65 startups chosen from nearly 1,500 global applicants — — Selected to…

9 minutes ago